In summary, berberin reduces COX-2/PGE2 levels, in turn dampens JAK2/STAT3 activation, leading to decreased expression of downstream target genes MMP-2/-9, resulting in less invasiveness and metastasis in CRC (Fig 7). The gene discussed is MMP2; the disease is colorectal carcinoma.